Patty Diez
@pattydiezh.bsky.social
170 followers
140 following
6 posts
#medphys in radiotherapy clinical trials working in @RTTQA.bsky.social at MVCC. Special interest in #SABR and #brachytherapy. Views my own
Posts
Media
Videos
Starter Packs
Reposted by Patty Diez
Reposted by Patty Diez
Reposted by Patty Diez
Marina Khan
@marina-khan.bsky.social
· Jun 7
Reposted by Patty Diez
Reposted by Patty Diez
Reposted by Patty Diez
Reposted by Patty Diez
Reposted by Patty Diez
RTTQA
@rttqa.bsky.social
· Apr 21
Regional Lymph Node Delineation variability and its Dosimetric Impact in Breast Cancer Radiotherapy
To quantify the interobserver variability of regional lymph node delineation for breast cancer radiotherapy (RT) and establish whether a relationship …
www.sciencedirect.com
Reposted by Patty Diez
Reposted by Patty Diez
Alison Tree
@alison-tree.bsky.social
· Mar 10
Stereotactic body radiotherapy for oligoprogressive disease in androgen suppressed prostate cancer: Primary endpoint analysis of the TRAP trial
Optimal management of oligoprogressive prostate cancer whilst on androgen receptor pathway inhibitors (ARPi) is not known. The **** trial tests the ro…
www.sciencedirect.com
Patty Diez
@pattydiezh.bsky.social
· Mar 3
Reposted by Patty Diez
Reposted by Patty Diez
Reposted by Patty Diez
Gerry Hanna
@gerryhanna.bsky.social
· Jan 3
Population-health impact of new drugs recommended by the National Institute for Health and Care Excellence in England during 2000–20: a retrospective analysis
During 2000–20, NHS coverage of new drugs displaced more population health than it generated. Our results highlight the inherent trade-offs between individuals who directly benefit from new drugs and those who forgo health due to the reallocation of resources towards new drugs.
www.thelancet.com
Reposted by Patty Diez
Reposted by Patty Diez